LTB4R and Alzheimer disease: Although clinical trials failed to show significant efficacy of montelukast against AD, intervention in the LTB4–BLT1 pathway via 5-LO inhibition might be effective since LTB4 seems to be the most potent LT with respect to triggering the proinflammatory cascade and recruitment of Th2 cells; by contrast, CysLTs are involved in the chronic inflammatory course of AD [136,137,138].